Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Companion FOAs:

 

PAR-21-122 , R61R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
PAR-21-123 , R61R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II

Deadlines:

  • Application Due Dates: June 17, 2021; Oct 19, 2021; Feb 22, 2022; June 21, 2022; Oct 18, 2022; Feb 21, 2023; June 20, 2023; Oct 20, 2023; Feb 20, 2024

PAR-21-124 Expiration Date February 21, 2024

Agency Website

Amount

$750,000

Amount Description

Direct costs cannot exceed $499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed $750,000.

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Interdisciplinary
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 22, 2022